Debulking Conventional Chemotherapy before Treatment By Anti-BCMA Bispecific Antibody in Extramedullary and/or High Tumor Burden Relapsed/Refractory Multiple MyelomaThomas Chalopin, Salomon Manier, Caroline Jacquet et al.|Blood|2024Cited by 3
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort studyThomas Chalopin, Elise Cellerin, Hélène Demarquette et al.|Blood Cancer Journal|2025Cited by 2
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort studyThomas Chalopin, Elise Cellerin, Hélène Demarquette et al.|Research Square|2025Cited by 0